Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CD40L GVAX

Next Previous
X
Search
Drug Profile

CD40L GVAX

Alternative Names: Autologous tumour cell-based vaccine; Bystander vaccine; Bystander-based autologous tumour cell vaccine; CD40LGVAX; Dendristim vaccine; GM-CSF/CD40L; GM.CD40L; GM.CD40L bystander vaccine; hCD40L/hGM-CSF

Latest Information Update: 27 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of South Florida
  • Developer H. Lee Moffitt Cancer Center and Research Institute
  • Class Antineoplastics; Cancer vaccines; CD antigens; Cell therapies; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Lung cancer; Malignant melanoma
  • No development reported Myelodysplastic syndromes

Most Recent Events

  • 20 Nov 2023 Cellular Biomedicine Group is now called AbelZeta Pharma
  • 28 Dec 2021 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Second-line therapy or greater) in USA (Intradermal, Injection)
  • 11 Dec 2019 CD40L GVAX is still in phase I trials for Myelodysplastic-syndromes (Combination therapy, Second-line therapy or greater) in USA (Intradermal, Injection) (NCT00840931)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top